-
Government Funding for the Development of Enzalutamide JAMA Oncol. (IF 22.5) Pub Date : 2024-12-19 Bishal Gyawali, Emily H. Jung, Helen Mooney, Jerry Avorn, Aaron S. Kesselheim
This cross-sectional study assesses the various patents and US government grants that were critical to the publicly funded development of the cancer drug enzalutamide.
-
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma JAMA Oncol. (IF 22.5) Pub Date : 2024-12-19 Laura A. Dawson, Kathryn A. Winter, Jennifer J. Knox, Andrew X. Zhu, Sunil Krishnan, Chandan Guha, Lisa A. Kachnic, Michael T. Gillin, Theodore S. Hong, Timothy D. Craig, Terence M. Williams, Ali Hosni, Eric Chen, Anne M. Noonan, Eugene J. Koay, Rishi Sinha, Michael I. Lock, Nitin Ohri, Jennifer A. Dorth, Guila Delouya, Anand Swaminath, Jennifer Moughan, Christopher H. Crane
ImportanceMost patients with locally advanced hepatocellular carcinoma (HCC) recur within the liver following systemic therapy.ObjectiveTo determine whether stereotactic body radiation therapy (SBRT) improves outcomes in patients with locally advanced HCC compared with sorafenib alone.Design, Setting, and ParticipantsThis multicenter phase 3 randomized clinical trial randomized patients with HCC 1:1
-
Assessing the Risk of Radiation Myelitis in Hypofractionated Stereotactic Body Radiation Therapy-Tolerance Is in the Eye of the Beholder. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-19 Evangelia Katsoulakis,Daniel E Spratt
-
Radiation Myelitis Risk After Hypofractionated Spine Stereotactic Body Radiation Therapy JAMA Oncol. (IF 22.5) Pub Date : 2024-12-19 Christopher B. Jackson, Lillian A. Boe, Lei Zhang, Aditya Apte, Lisa M. Ruppert, Justin M. Haseltine, Boris A. Mueller, Adam M. Schmitt, Jonathan T. Yang, W. Christopher Newman, Ori Barzilai, Mark H. Bilsky, Yoshiya Yamada, Andrew Jackson, Eric Lis, Daniel S. Higginson
ImportanceStereotactic body radiation therapy (SBRT) for spinal metastases improves symptomatic outcomes and local control compared to conventional radiotherapy. Treatment failure most often occurs within the epidural space, where dose is constrained by the risk of radiation myelitis (RM). Current constraints designed to prevent RM after spine SBRT are derived from limited data.ObjectiveTo characterize
-
Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-12-12 Charlie A. Hamm, Patrick Asbach, Anna Pöhlmann, Ivo G. Schoots, Veeru Kasivisvanathan, Thomas O. Henkel, Manfred Johannsen, Thomas Speck, Alexander D. J. Baur, Matthias Haas, Federico Collettini, Tobias Penzkofer, Lynn J. Savic, Frank Konietschke, Lothar Weißbach, Bernd Hamm, Frank König, Hannes Cash
ImportanceThe magnetic resonance imaging (MRI) pathway for diagnosing clinically significant prostate cancer (csPCa; defined as International Society of Urological Pathology grade group ≥2) uses multiparametric MRI (mpMRI) for prostate biopsy (PB) decision-making. However, the intermediate impact on patient outcomes in men with negative MRI results avoiding PB and men with positive MRI results without
-
Polygenic Risk Scores for Prostate Cancer: Informing Prevention or Therapy. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-12 Konrad H Stopsack
-
Polygenic Risk Score and Upgrading in Patients With Prostate Cancer Receiving Active Surveillance JAMA Oncol. (IF 22.5) Pub Date : 2024-12-12 Louisa B. Goss, Menghan Liu, Yingye Zheng, Boya Guo, David V. Conti, Christopher A. Haiman, Linda Kachuri, William J. Catalona, John S. Witte, Daniel W. Lin, Lisa F. Newcomb, Burcu F. Darst
ImportanceActive surveillance is the preferred management strategy for patients with low- or favorable intermediate-risk prostate cancer (PCa); however, frequent health care visits can be costly and burdensome to patients. Identifying patients who may benefit from intensive vs passive surveillance could reduce these burdens.ObjectiveTo investigate associations between a polygenic risk score (PRS) and
-
Bilateral Mastectomy vs Lumpectomy and Breast Cancer Mortality Risk-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-12 Steven A Narod,Vasily Giannakeas
-
Bilateral Mastectomy vs Lumpectomy and Breast Cancer Mortality Risk. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-12 Thomas J O'Keefe,Michael D Alvarado,Laura J Esserman
-
Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy JAMA Oncol. (IF 22.5) Pub Date : 2024-12-12 Shyam A. Patel, Jay Y. Spiegel, Saurabh Dahiya
ImportanceThe commercialization of chimeric antigen receptor–T-cell (CAR-T) therapy has changed the landscape of treatment of hematological cancers. Numerous studies from the early 2000s paved the way for cell-based targeted therapeutics, which have been established as practice-changing therapies in lymphoma, leukemia, and multiple myeloma. However, there has been some recent concern about the risk
-
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-12 Ann H Partridge,Terry Hyslop,Shoshana M Rosenberg,Antonia V Bennett,Sarah Drier,Mattias Jonsson,Ayako Shimada,Yutong Li,Yan Li,Thomas Lynch,Elizabeth Frank,Deborah Collyar,Desiree Basila,Donna Pinto,Anna Weiss,Anna Wolf,Kelsey Norris,Meredith Witten,Marc Boisvert,Armando Giuliano,Kelsey E Larson,Kathleen Yost,Priscilla F McAuliffe,Amy Krie,Nina Tamirisa,Sonja Darai,Lisa Carey,Alastair Thompson,E Shelley
Importance Active monitoring (AM) for low-risk ductal carcinoma in situ (DCIS) has been considered as a potential alternative to guideline-concordant care (GCC; inclusive of surgery with or without radiation). Reported data comparing patient-reported outcomes (PROs) between GCC and AM for DCIS are lacking. Objective To compare PROs at baseline and over time in patients with low-risk DCIS randomized
-
Neoadjuvant Exercise Therapy in Patients With Prostate Cancer-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-05 Lee W Jones,Behfar Ehdaie,Paul C Boutros
-
Neoadjuvant Exercise Therapy in Patients With Prostate Cancer. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-05 Fabian Falkenbach,Lars Budäus
-
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-12-05 Hyo S. Han, Amy L. Aldrich, Saurabh K. Garg, R. Jared Weinfurtner, Jonathan V. Nguyen, Qianxing Mo, Junmin Whiting, Jennifer Childress, Hatem Soliman, Ricardo Costa, Avan Armaghani, Aixa Soyano, John Kiluk, Susan Hoover, Marie C. Lee, Nazanin Khakpour, Nithin Shenoi, Zena Jameel, Gary K. Koski, Brian J. Czerniecki
ImportanceCurrent chemotherapy regimens for patients with ERBB2 (formerly HER2)–positive breast cancer are associated with considerable morbidity. These patients may benefit from more effective and less toxic therapies.ObjectiveTo evaluate the safety, immunogenicity, and preliminary efficacy of intratumoral (IT) delivery of conventional type 1 dendritic cells (cDC1) in combination with ERBB2-targeted
-
Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020 JAMA Oncol. (IF 22.5) Pub Date : 2024-12-05 Katrina A. B. Goddard, Eric J. Feuer, Jeanne S. Mandelblatt, Rafael Meza, Theodore R. Holford, Jihyoun Jeon, Iris Lansdorp-Vogelaar, Roman Gulati, Natasha K. Stout, Nadia Howlader, Amy B. Knudsen, Daniel Miller, Jennifer L. Caswell-Jin, Clyde B. Schechter, Ruth Etzioni, Amy Trentham-Dietz, Allison W. Kurian, Sylvia K. Plevritis, John M. Hampton, Sarah Stein, Liyang P. Sun, Asad Umar, Philip E. Castle
ImportanceCancer mortality has decreased over time, but the contributions of different interventions across the cancer control continuum to averting cancer deaths have not been systematically evaluated across major cancer sites.ObjectiveTo quantify the contributions of prevention, screening (to remove precursors [interception] or early detection), and treatment to cumulative number of cancer deaths
-
A Values Proposition for Cancer Care JAMA Oncol. (IF 22.5) Pub Date : 2024-12-05 William E. Rosa, Andrew S. Epstein, Judith E. Nelson
This Viewpoint discusses what a value proposition could look like in oncology and how it should reflect a clinician’s commitment to partner with patients to improve outcomes through individualized communication and shared decision-making centered on the patient’s values.
-
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-11-27 Amanda L Blackford,Marcia Irene Canto,Michael Goggins
-
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance. JAMA Oncol. (IF 22.5) Pub Date : 2024-11-27 Christopher Dasaro,Vinay Prasad
-
Colorectal Cancer Incidence and Mortality After Negative Colonoscopy Screening Results JAMA Oncol. (IF 22.5) Pub Date : 2024-11-27 Markus Dines Knudsen, Kai Wang, Liang Wang, Georgios Polychronidis, Paula Berstad, Anette Hjartåker, Zhe Fang, Shuji Ogino, Andrew T. Chan, Mingyang Song
ImportanceThe current recommendation for a 10-year rescreening interval after a negative colonoscopy screening (NCS) result has been questioned, with some studies showing a persistently lower risk of colorectal cancer (CRC) after NCS results.ObjectiveTo examine long-term CRC incidence and mortality after NCS results (ie, no presence of CRC or polyps) and according to a risk score based on major demographic
-
Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies JAMA Oncol. (IF 22.5) Pub Date : 2024-11-27 Michael V. Gormally, Monica F. Chen, Anne Marie Noronha, Kristalla Panageas, Maggie Reynolds, Kaelyn Kohlasch, Bryan Novak, Tatiana Kee-Velez, Nikeysha Clarke, Michael Eubank, Cynthia Chu, Clare Wilhelm, Amanda Blouin, Chrisann Kyi, Claire Friedman, Charles M. Rudin, Mark G. Kris, Ronak Shah, David Aggen, Sandra D’Angelo, Alexander N. Shoushtari, Michael F. Berger, Chaitanya Bandlamudi, Christopher
This case series evaluates whether human leukocyte antigen (HLA) genotype could be inferred from standard next-generation sequencing, comparing concordance with confirmatory whole-exome sequencing and assessing if this assisted in matching patients to clinical trials.
-
Targeting CNS Metastases in Non–Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers JAMA Oncol. (IF 22.5) Pub Date : 2024-11-27 Jyoti Malhotra, Isa Mambetsariev, Gregory Gilmore, Jeremy Fricke, Arin Nam, Natalie Gallego, Bihong T. Chen, Mike Chen, Arya Amini, Rimas V. Lukas, Ravi Salgia
ImportanceCentral nervous system (CNS) metastases presenting as either brain parenchymal metastases or leptomeningeal metastases are diagnosed in up to 50% of patients with advanced non–small cell lung cancer during their disease course. While historically associated with a poor prognosis due to limited treatment options, the availability of an increasing number of targeted therapies with good CNS
-
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib JAMA Oncol. (IF 22.5) Pub Date : 2024-11-21 Elias Jabbour, Vivian G. Oehler, Paul B. Koller, Omer Jamy, Elza Lomaia, Anthony M. Hunter, Olga Uspenskaya, Svetlana Samarina, Sudipto Mukherjee, Jorge E. Cortes, Maria R. Baer, Vera Zherebtsova, Vasily Shuvaev, Anna Turkina, Igor Davydkin, Huanshan Guo, Zi Chen, Tommy Fu, Lixin Jiang, Cunlin Wang, Hengbang Wang, Dajun Yang, Yifan Zhai, Hagop Kantarjian
ImportancePatients with chronic myeloid leukemia (CML) or Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL) resistant or intolerant to BCR-ABL1 tyrosine kinase inhibitors (TKIs) have limited treatment options. Olverembatinib, which is approved in China, has only been tested in Chinese patients.ObjectiveTo assess the pharmacokinetics, safety, efficacy, and recommended dose of olverembatinib
-
A SEER Registry–Based Analysis of Pediatric Colorectal Adenocarcinomas JAMA Oncol. (IF 22.5) Pub Date : 2024-11-21 Sameh Hany Emile, Nir Horesh, Zoe Garoufalia, Rachel Gefen, Justin Dourado, Steven D. Wexner
This cohort study analyzes the characteristics of colorectal cancer in pediatric patients using Surveillance, Epidemiology, and End Results (SEER) registry data.
-
FOLFOX/FOLFIRI-Bevacizumab for Unresectable Colorectal Liver Metastases. JAMA Oncol. (IF 22.5) Pub Date : 2024-11-21 Jan Franko,Viet H Le
-
More on Waterpipe Tobacco Smoking and Cancer Mortality Content. JAMA Oncol. (IF 22.5) Pub Date : 2024-11-21 Ping-Hao Chiang,Chieh-Hsuan Tsai
-
More on Waterpipe Tobacco Smoking and Cancer Mortality Content -Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-11-21 Ngoan Tran Le,Jian-Min Yuan,Hung N Luu
-
First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial. JAMA Oncol. (IF 22.5) Pub Date : 2024-11-21 Marinde J G Bond,Karen Bolhuis,Olaf J L Loosveld,Jan Willem B de Groot,Helga Droogendijk,Helgi H Helgason,Mathijs P Hendriks,Joost M Klaase,Geert Kazemier,Mike S L Liem,Arjen M Rijken,Cornelis Verhoef,Johannes H W de Wilt,Koert P de Jong,Michael F Gerhards,Martinus J van Amerongen,Marc R W Engelbrecht,Krijn P van Lienden,John J Hermans,I Quintus Molenaar,Dirk J Grünhagen,Bart de Valk,Brigitte C M Haberkorn
Importance In patients with colorectal cancer and unresectable liver-only metastases (CRLM), treatment with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) plus irinotecan (FOLFOXIRI) and bevacizumab vs FOLFOX/folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus bevacizumab increased progression-free survival, response, and R0/R1 resection/ablation rates, as well as toxic effects in RAS/BRAFV600E-variant
-
Toripalimab For Extensive-Stage Small Cell Lung Cancer. JAMA Oncol. (IF 22.5) Pub Date : 2024-11-14 Ayse Ece Cali Daylan,Daniel Morgensztern,Saiama N Waqar
-
Concerns Regarding Sample Size and Credibility of Progression-Free Survival Results. JAMA Oncol. (IF 22.5) Pub Date : 2024-11-14 Xiaoling Xu,Lisha Ye,Yaping Xu
-
Concerns Regarding Sample Size and Credibility of Progression-Free Survival Results-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-11-14 Song Dong,Hong-Hong Yan,Yi-Long Wu
-
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-11-14 Ying Cheng, Wei Zhang, Lin Wu, Caicun Zhou, Donglin Wang, Bing Xia, Minghong Bi, Xiuhua Fu, Chong Li, Dongqing Lv, Yanqiu Zhao, Gongyan Chen, Tienan Yi, Jianan Huang, Min Li, Runxiang Yang, Xiaoping Huang, Ye Wang, Mingjun Zhang, Yueyin Pan, Yilan Sun, Sheng Hu, Xiqin Zhang, Min Zhou, Jian Fang, Faguang Jin, Yunpeng Liu, Yinyin Li, Zhihong Zhang, Jie Hu, Laiyu Liu, Rui Wang, Yan Li, Kangsheng Gu, Cuimin
ImportancePatients with extensive-stage small cell lung cancer (ES-SCLC) have poor prognoses and unmet medical needs.ObjectiveTo evaluate the efficacy and safety of toripalimab plus etoposide and platinum-based chemotherapy (EP) vs placebo plus EP as a first-line treatment for patients with ES-SCLC.Design, Setting, and ParticipantsThis multicenter, double-blind, placebo-controlled phase 3 randomized
-
Regulatory Fate of Cancer Indications in the European Union After Accelerated Approval in the US JAMA Oncol. (IF 22.5) Pub Date : 2024-11-14 Tonny Studsgaard Petersen, Kristian Karstoft, Freja Karuna Hemmingsen Sørup, Marie Lund, Allan Cramer
This cohort study investigates the regulatory fate in the European Union for drugs that received accelerated approval for cancer indications in the US.
-
Advancing Global Pharmacoequity in Oncology JAMA Oncol. (IF 22.5) Pub Date : 2024-11-14 Parsa Erfani, Ruth L. Okediji, Vivienne Mulema, Edward R. Scheffer Cliff, Kwanele Asante-Shongwe, Brittany L. Bychkovksy, Temidayo Fadelu
ImportanceLimited availability and affordability of cancer drugs contribute to staggering disparities in cancer survival between high-income and low- and middle-income countries (LMICs). As infrastructure for cancer care rapidly develops, there is an urgent need to reduce prices and improve access to cancer medicines in LMICs to advance pharmacoequity globally.ObservationsPrior strategies to expand
-
PD-L1 Expression for Tailoring Treatment in Advanced Melanoma-It Is Never That Easy-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-11-07 Marco Donia,Inge Marie Svane
-
PD-L1 Expression for Tailoring Treatment in Advanced Melanoma-It Is Never That Easy. JAMA Oncol. (IF 22.5) Pub Date : 2024-11-07 Latif Karahan,Mutlu Hayran,Omer Dizdar
-
Financial Toxicity Among Asian American Cancer Survivors JAMA Oncol. (IF 22.5) Pub Date : 2024-11-07 Stephanie Wang, Fumiko Chino, Edward Christopher Dee
This Viewpoint highlights financial toxicity specific to Asian American cancer survivors and presents steps forward within the framework of the social ecological model of health, considering individual, interpersonal, community, and policy-level dimensions.
-
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma JAMA Oncol. (IF 22.5) Pub Date : 2024-11-07 Chunrui Li, Keshu Zhou, Yongxian Hu, Dehui Zou, Lijuan Chen, Bing Chen, Jing Liu, Xi Zhang, Hanyun Ren, Kai Hu, Peng Liu, Jian-Qing Mi, Zhenyu Li, Kaiyang Ding, Di Wang, Wen Wang, Songbai Cai, Jianyong Li, Yongping Song, He Huang, Lugui Qiu
ImportanceEquecabtagene autoleucel (eque-cel), a fully human-derived B-cell maturation antigen-targeting chimeric antigen receptor (CAR) T-cell therapy, has exhibited potential for the treatment of relapsed or refractory multiple myeloma (RRMM), and further investigation in a larger cohort is necessary.ObjectiveTo evaluate whether eque-cel can benefit patients with RRMM and determine the overall response
-
Long-Term Adverse Effects and Complications After Prostate Cancer Treatment JAMA Oncol. (IF 22.5) Pub Date : 2024-11-07 Joseph M. Unger, Cathee Till, Catherine M. Tangen, Dawn L. Hershman, Phyllis J. Goodman, Michael LeBlanc, William E. Barlow, Riha Vaidya, Lori M. Minasian, Howard L. Parnes, Ian M. Thompson
ImportanceDue to the often indolent nature of prostate cancer (PCA), treatment decisions must weigh the risks and benefits of cancer control with those of treatment-associated morbidities.ObjectiveTo characterize long-term treatment-related adverse effects and complications in patients treated for PCA compared to a general population of older males.Design, Setting, and ParticipantsThis cohort study
-
Expanding Clinical Trial Accessibility in the Digital Era With Telemedicine-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-01 Wade T Swenson
-
Expanding Clinical Trial Accessibility in the Digital Era With Telemedicine. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-01 Jiatong Ding,Shuhang Wang,Ning Li
-
Survival Outcomes of an Early Intervention Smoking Cessation Treatment After a Cancer Diagnosis JAMA Oncol. (IF 22.5) Pub Date : 2024-10-31 Paul M. Cinciripini, George Kypriotakis, Janice A. Blalock, Maher Karam-Hage, Diane M. Beneventi, Jason D. Robinson, Jennifer A. Minnix, Graham W. Warren
ImportanceSmoking after a cancer diagnosis increases mortality and risk for a second cancer.ObjectiveTo determine the association between time of entry into a smoking cessation intervention following a cancer diagnosis and survival outcomes.Design, Setting, and ParticipantsUsing a prospective cohort study design, patients with cancer who smoked and received cessation treatment were assessed at 3 months
-
Effects of the Oncology Industrial Complex on Academic Cancer Centers JAMA Oncol. (IF 22.5) Pub Date : 2024-10-31 S. Gail Eckhardt, Leonidas C. Platanias
This Viewpoint outlines the missions of academic cancer centers and how they are being affected by the oncology industrial complex along with challenges and suggestions for an aligned way forward.
-
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma JAMA Oncol. (IF 22.5) Pub Date : 2024-10-31 Jann N. Sarkaria, Karla V. Ballman, Sani H. Kizilbash, Erik P. Sulman, Caterina Giannini, Bret B. Friday, Nicholas A. Butowski, Nimish A. Mohile, David E. Piccioni, James D. Battiste, Jan Drappatz, Jian L. Campian, Sandeep Mashru, Kurt A. Jaeckle, Barbara J. O’Brien, Jesse G. Dixon, Brian F. Kabat, Nadia L. Laack, Leland S. Hu, Timothy Kaufmann, Priya Kumthekar, Benjamin M. Ellingson, S. Keith Anderson
ImportanceThe prognosis for patients with glioblastoma is poor following standard therapy with surgical resection, radiation, temozolomide, and tumor-treating fields.ObjectivesTo evaluate the combination of veliparib and temozolomide in glioblastoma based on preclinical data demonstrating significant chemosensitizing effects of the polyadenosine diphosphate-ribose polymerase 1/2 inhibitor veliparib
-
Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-01 Maria E Cabanillas,Ramona Dadu,Renata Ferrarotto,Maria Gule-Monroe,Suyu Liu,Bryan Fellman,Michelle D Williams,Mark Zafereo,Jennifer R Wang,Charles Lu,Matthew Ning,Brian A McKinley,Scott E Woodman,Dzifa Duose,Gary B Gunn,Naifa L Busaidy,
Importance Anaplastic thyroid carcinoma (ATC) is a rare and lethal cancer. Although progress has been made in recent years in patients with mutated BRAF tumors, those who respond initially eventually die of their disease; furthermore, there are no approved therapies for non-BRAF mutated tumors. Objective To determine whether treatment with matched-targeted therapy plus immune checkpoint inhibitors
-
Chemoimmunotherapy in Older Adults With Non-Small Cell Lung Cancer-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-01 Hajime Asahina,Yoko Tsukita,Takehiro Tozuka
-
Impacts of Immunotherapy on Patients With Aggressive Thyroid Carcinomas. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-01 Alfred King-Yin Lam
-
Chemoimmunotherapy in Older Adults With Non-Small Cell Lung Cancer. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-01 Hengjia Tu,Yuzhuo Zhang,Zhixuan You
-
Hairy Kidneys and Sclerotic Bone Lesions JAMA Oncol. (IF 22.5) Pub Date : 2024-10-24 Juan Esteban Velez-Hernandez, Julia T. Geyer, Mateo Mejia Saldarriaga
A 72-year-old man with a history of polycythemia vera (positive for JAK2 V617F) presented with several months of functional decline and weight loss. An 18F-fluorodeoxyglucose positron emission tomography/computed tomography showed soft tissue infiltrates and sclerosis of the perirenal spaces with fluorodeoxyglucose uptake. What is your diagnosis?
-
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma JAMA Oncol. (IF 22.5) Pub Date : 2024-10-24 Kartik Sehgal, Theodora Pappa, Kee-Young Shin, Julia Schiantarelli, Mofei Liu, Cora Ricker, Naomi R. Besson, Stephanie M. Jones, Emma L. Welsh, Kathleen L. Pfaff, Justine A. Barletta, Jihye Park, Brendan Reardon, Gerard M. Doherty, Erik K. Alexander, Scott J. Rodig, David A. Barbie, Anne O’Neill, Eliezer Van Allen, Robert I. Haddad, Jochen H. Lorch
ImportanceAggressive thyroid carcinoma, including radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC), and anaplastic thyroid carcinoma (ATC), are associated with significant morbidity and mortality and have limited therapeutic options. Distinct immune profiles have been identified in thyroid cancer subtypes suggesting they may be susceptible to immune
-
Cancer Drug Access and Innovation Under the Inflation Reduction Act—A Balancing Act JAMA Oncol. (IF 22.5) Pub Date : 2024-10-24 Stacie B. Dusetzina, Frank S. David
This Viewpoint explores whether the Inflation Reduction Act’s provisions and price negotiations could affect investment in trials of new oncology therapies or indications.
-
Considerations of Lay Health Worker Intervention Among Patients With Advanced Cancer-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-01 Manali I Patel
-
Considerations of Lay Health Worker Intervention Among Patients With Advanced Cancer. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-01 Kai Kang,Yijun Wu
-
Comment on Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-01 Omar El-Taji,Ashwin Sachdeva
-
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-01 Nathalie Gaspar,Giun-Yi Hung,Sandra J Strauss,Quentin Campbell-Hewson,Filemon S Dela Cruz,Julia L Glade Bender,Kyung-Nam Koh,Sarah B Whittle,Godfrey Chi-Fung Chan,Nicolas U Gerber,Sauli Palmu,Daniel A Morgenstern,Alessandra Longhi,Fredrik Baecklund,Jun Ah Lee,Franco Locatelli,Catalina Márquez Vega,Katherine A Janeway,Geoffrey McCowage,Martin G McCabe,Behzad Bidadi,Jie Huang,Jodi McKenzie,Chinyere E
Importance The combination of ifosfamide and etoposide (IE) is commonly used to treat relapsed or refractory osteosarcoma; however, second-line treatment recommendations vary across guidelines. Objective To evaluate whether the addition of lenvatinib to IE (LEN-IE) improves outcomes in children and young adults with relapsed or refractory osteosarcoma. Design, Setting, and Participants The OLIE phase
-
Diet Quality, Dietary Inflammatory Potential, and Risk of Prostate Cancer Grade Reclassification JAMA Oncol. (IF 22.5) Pub Date : 2024-10-17 Zhuo Tony Su, Mufaddal Mamawala, Patricia K. Landis, Claire M. de la Calle, Nitin Shivappa, Michael Wirth, James R. Hébert, Christian P. Pavlovich, Bruce J. Trock
ImportanceIt remains unclear whether diet may influence the risk of prostate cancer grade reclassification in men undergoing active surveillance.ObjectiveTo assess the association of diet quality and dietary inflammatory potential with prostate cancer grade reclassification during active surveillance.Design, Setting, and ParticipantsThis prospective cohort study included men diagnosed with grade group
-
Staging and Prognosis of Nasopharyngeal Cancer: The Time for Change Is Now. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-10 Sweet Ping Ng,Darrion Mitchell
-
Differences in Sentinel Node Biopsy and Targeted Axillary Dissection Following Neoadjuvant Chemotherapy. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-10 Mangesh A Thorat
-
Differences in Sentinel Node Biopsy and Targeted Axillary Dissection Following Neoadjuvant Chemotherapy-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-10 Giacomo Montagna,Monica Morrow,Walter P Weber
-
Implementing Resource-Stratified Guidelines in LMICs—More Issues Than Solutions JAMA Oncol. (IF 22.5) Pub Date : 2024-10-10 Shweta Baral
This Viewpoint discusses the importance of formulating more stable local treatment guidelines because international guidelines and even resource-stratified guidelines may not be as applicable in low- to middle-income countries.
-
Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging Classification JAMA Oncol. (IF 22.5) Pub Date : 2024-10-10 Jian-Ji Pan, Hai-Qiang Mai, Wai Tong Ng, Chao-Su Hu, Jin-Gao Li, Xiao-Zhong Chen, James C. H. Chow, Edwin Wong, Victor Lee, Ling-Yu Ma, Qiao-Juan Guo, Qin Liu, Li-Zhi Liu, Ting-Ting Xu, Xiao-Chang Gong, Meng-Yun Qiang, Kwok-Hung Au, Tsz-Chim Liu, Chi Leung Chiang, You-Ping Xiao, Shao-Jun Lin, Yun-Bin Chen, Shan-Shan Guo, Charlene H. L. Wong, Lin-Quan Tang, Zhi-Yuan Xu, Yi-Zhen Jia, Wen-Sa Peng, Li-Ping
ImportanceAccurate staging is a fundamental step in treating patients with nasopharyngeal carcinoma (NPC) worldwide; this is crucial not only for prognostication, but also for guiding treatment decisions. The American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) tumor-node-metastasis (TNM) system is the global language for clinicians, researchers, and cancer registries